Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.

Autor: Partanen, Anu1 (AUTHOR) anu.partanen@pshyvinvointialue.fi, Waage, Anders2 (AUTHOR) anders.waage@ntnu.no, Peceliunas, Valdas3 (AUTHOR) valdas.peceliunas@santa.lt, Schjesvold, Fredrik4,5 (AUTHOR) fredrikschjesvold@gmail.com, Anttila, Pekka6 (AUTHOR) pekka.anttila@hus.fi, Säily, Marjaana7 (AUTHOR) marjaana.saily@pohde.fi, Uttervall, Katarina8,9 (AUTHOR) katarina.uttervall@regionstockholm.se, Putkonen, Mervi10 (AUTHOR) mervi.putkonen@tyks.fi, Carlson, Kristina11 (AUTHOR) kristina.carlson@akademiska.se, Haukas, Einar12 (AUTHOR) haer@sus.no, Sankelo, Marja13 (AUTHOR) marja.sankelo@pirha.fi, Szatkowski, Damian14 (AUTHOR) damian.lukasz.szatkowski@helse-forde.no, Hansson, Markus15 (AUTHOR) markus.hansson@skane.se, Marttila, Anu16 (AUTHOR) anu.marttila@kymenhva.fi, Svensson, Ronald17 (AUTHOR) ronald.svensson@regionostergotland.se, Axelsson, Per18 (AUTHOR) per.axelsson@skane.se, Lauri, Birgitta19 (AUTHOR) birgitta.lauri@norrbotten.se, Mikkola, Maija20 (AUTHOR) maija.mikkola@paijatha.fi, Karlsson, Conny21 (AUTHOR), Abelsson, Johanna22 (AUTHOR) johanna.abelsson@vgregion.se
Zdroj: Cancers. Mar2024, Vol. 16 Issue 5, p1024. 15p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje